GinPolMedProject ©
3 (61) 2021 : 001-07
• ORIGINAL RESEARCH
The High-risk Human Papilloma Virus (Hr-HPV) in abnormal
pap smears
Ihab I. Samaha1 (CDEF), Ibrahim A. Abdelazim 2,3* (ABDE), Tamer E. El-Ghazaly2 (CDEF)
1
Department of Obstetrics and Gynecology, Faculty of Medicine, Helwan University, Cairo, Egypt.
Department of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
3
Department of Obstetrics and Gynecology, Kuwait Oil Company (KOC), Ahmadi, Kuwait.
SUMMARY
2
AUTHORS’ CONTRIBUTION: (A) Study Design · (B) Data Collection
. (C) Statistical Analysis · (D) Data Interpretation · (E) Manuscript
Preparation · (F) Literature Search · (G) Funds Collection
Background: The Human papilloma virus (HPV) is the commonest
sexually transmitted disease (STD) in low- and middle-income countries
and it is the most powerful carcinogens implicated in cervical cancer.
Objectives: To detect types of Hr-HPV in abnormal Pap smears and
cervical cytology abnormalities associated with Hr-HPV infection.
M ethods: Women eligible for Pap smears and HPV-co-testing according
to hospital protocol were included in this study. Pap smears were done
using the liquid-based cytology (LBC) and evaluated according to the
Bethesda system. HPV-DNA co-testing was done using the Anyplex-II.
Collected data were statistically analyzed to detect types of Hr-HPV in
abnormal Pap smears, and cervical cytology abnormalities associated
with Hr-HPV infection.
Results: The prevalence of Hr-HPV in abnormal Pap smears was 48.2%
(106/220). The Hr-HPV detected in abnormal Pap smears were HPV-16
(36.8% (39/106)), HPV-31 (12.3% (13/106)), HPV-58 (11.3% (12/106)),
HPV-66 (10.4% (11/106)), HPV-51 (9.4% (10/106)), HPV-18 (7.5%
(8/106)), while multiple Hr-HPVs-35, -33, -52, and 58 were detected in
12.3% (13/106) of abnormal Pap smears.
The Hr- HPV detected in 39.6% (42/106) of ASCUS, in 80.2% (85/106)
of LSIL, in 81.1% (86/106) of ASC-H, and in 83.01 (88/106) of HSIL. The
Hr-HPV detection rate was significantly higher in LSIL, ASC-H, and HSIL
compared to ASCUS (P=0.002, 0.001 and 0.001, respectively).
Conclusion: The prevalence of Hr-HPV in abnormal Pap smears
was 48.2%. The low prevalence of HPV-18 in this study confirms the
variations in genotype distribution of Hr-HPV.
The Hr-HPV detection rate was significantly higher in LSIL, ASC-H, and
HSIL compared to ASCUS. This finding supports the recommendation
of HPV co-testing with routine Pap smear in women aged 30-65 years.
Keyw ords: High-Risk; HPV; Cervical; Pap; Cytology
Address for correspondence:
Ibrahim A. Abdelazim
Department of Obstetrics and Gynecology, Kuwait Oil Company
(KOC), Ahmadi, Kuwait.
Tel: +965-66551300
E-mail: dr.ibrahimanwar@gmail.com
Word count: 1674 Tables: 2 Figures: 0 References: 24
Received: 20.08.2021
Accepted: 06.09.2021
Published: 28.09.2021
INTRODUCTION
Cancer cervix is an ideal malignancy for screening and
prevention because it can be diagnosed and treated at
the pre-cancerous lesions before development of invasive
disease [1-3].
Most cervical cancers develop from infected cells with
high-risk human papilloma virus (Hr-HPV), originated
from the squamo-columnar junction of the cervix [4].
The HPV is the commonest sexually transmitted disease
(STD) in low- and middle-income countries and it is the
most powerful carcinogens implicated in cervical cancer [5].
Since the causal link between cervical cancer and Hr-HPV
infection was established, much effort has been devoted for
diagnosis and prevention of HPV infection [6,7].
The liquid-based cytology (LBC) approved by the
FDA in 1996 as an alternative to conventional cervical
smear (CCS) [8,9]. The polymerase chain reaction (PCR)
based methods for detection of HPV deoxyribonucleic
acid (DNA) is highly sensitive and specific, and it
has the additional advantages of detecting small viral
concentrations [10].
Initially, the Hr-HPV co-testing was recommended
for ASC-US [11]. Based on the recommendations from
National Institute of Health (NIH), American Society
for Colposcopy and Cervical Pathology (ASCCP), and
American Cancer Society (ACS) [12], the FDA in 2014
approved the Hr-HPV co-testing as primary screening of
cervical cancer in women ≥25 years at intervals ≥3 years [13].
The joint recommendation released in 2012 advocates
HPV co-testing in conjunction with routine Pap smear
in women aged 30-65 years [14]. The co-testing increases
the detection of cervical-intraepithelial lesion-2 (CIN2)
or greater lesions at baseline screening, and significantly
decreases the detection of CIN2/CIN3 lesions at subsequent
screening compared to cytology alone [15]. Variation in the
genotype distribution of Hr-HPV was reported in previous
studies [16-18]. Therefore, this study design to detect types
of Hr-HPV in abnormal Pap smears and cervical cytology
abnormalities associated with Hr-HPV infection.
OBJECTIVES
To detect types of Hr-HPV in abnormal Pap smears
and cervical smear abnormalities associated with Hr-HPV
infection.
−1
© GinPolMedProject 3 (61) 2021: 001-007
MATERIALS AND METHODS
Sample Size
Women eligible for Pap smears and HPV-co-testing
according to hospitals protocol were included in this
prospective study which was conducted over two years from
January 2019 till January 2021, after informed consents in
accordance with Helsinki declaration to detect the types
of Hr-HPV in abnormal Pap smears and cervical smear
abnormalities associated with Hr-HPV infection.
The required sample size calculated using G Power
software version 3.1.9.7 for sample size calculation, setting
α -error probability at 0.05, power (1-β error probability)
at 0.95%, and effective sample size (w) at 0.5. An effective
sample ≥220 Pap smears was needed to produce a
statistically accepted acceptable figure.
Eligibility to Pap smear and HPV-co-testing include
sexually active women, between 25-65 years old. Women
received HPV vaccine; previous abnormal Pap smear,
previous hysterectomy, previous genital malignancy,
women under treatment for genital tract malignancy (i.e.,
either chemo and/or radiotherapy) or women refused to
participate and/or to give consent were excluded from this
study.
Pap smears were done using the LBC and evaluated
according to the Bethesda system. HPV-DNA testing was
done using the Anyplex-II (Anyplex, Seoul, South Korea)
which is a semi-quantitative real-time PCR test utilizing
dual priming oligonucleotide and tagging oligonucleotide
cleavage.
Anyplex-II provides sensitive and specific genotyping
information of 28 HPV types (19 Hr-HPV types and 9
low-risks HPV (Lr-HPV)) in single reaction.
The abnormal cervical cytology was classified as atypical
squamous cells of undetermined significance (ASCUS),
low-grade and high-grade squamous intraepithelial lesion
(LSIL and HSIL), atypical squamous cells cannot exclude
HSIL (ASC-H), squamous cell carcinoma (SCC), atypical
glandular cells not otherwise specified (AGC-NOS),
atypical glandular cells suspicious of adenocarcinoma or in
situ carcinoma (AGC neoplastic) [1].
Women with abnormal Pap smears and/or Hr-HPV
positivity were offered colposcopy examination and cervical
biopsy. The biopsy specimens were examined and graded as
CIN1, CIN2, CIN3, in situ carcinoma or invasive cancer.
Collected data were statistically analyzed to detect types of
Hr-HPV in abnormal Pap smears (primary outcome) and
cervical cytology abnormalities associated with Hr-HPV
infection (secondary outcome).
Tab. 1. Types of Hr-HPV and Lr-HPV
detected in abnormal Pap smears.
Statistical Analysis
Categorical variables will be presented as number and
percentage. Chi-square test (x2) was used for analysis
of qualitative variables to detect types of Hr-HPV in
abnormal Pap smears (primary outcome) and cervical
cytology abnormalities associated with Hr-HPV infection
(secondary outcome). P<0.05 was considered significant.
RESULTS
Prevalence of HPV in abnormal Pap smears: Four
hundred and thirty (430) cervical cytology specimens
were collected from January 2019 to January 2021 for
Pap smears and HPV co-testing, 51.2% (220/430) of the
collected cervical cytology specimens had abnormal Pap
smear results, and 55.5% (122/220) of the abnormal Pap
smears were positive for HPV (Hr-HPV and Lr-HPV).
The prevalence of Hr-HPV in abnormal Pap smears was
48.2% (106/220).
Types of Hr-HPV in abnormal Pap smears: The
Hr-HPV detected in abnormal Pap smears were HPV-16
(36.8% (39/106)), HPV-31 (12.3% (13/106)), HPV-58
(11.3% (12/106)), HPV-66 (10.4% (11/106)), HPV-51
(9.4% (10/106)), HPV-18 (7.5% (8/106)), while multiple
Hr-HPVs-35, -33, -52, and 58 were detected in 12.3%
(13/106) of abnormal Pap smears (Tab. 1.).
Lr-HPV detected in abnormal Pap smears include
HPV-6 (37.5% (6/16)), HPV-40 (25% (4/16)), HPV-44
(18.75% (3/16)), and HPV-61 (18.75% (3/16)) (Tab. 1.).
The cervical cytology abnormalities associated with
Hr-HPV infection: The Hr- HPV detected in 39.6%
(42/106) of ASCUS, in 80.2% (85/106) of LSIL, in 81.1%
(86/106) of ASC-H, and in 83.01 (88/106) of HSIL. The
Hr-HPV detection rate was significantly higher in LSIL,
Type of HPV
Number and (%)
Hr-HPV
HPV-16
36.8% (39/106)
HPV-31
12.3% (13/106)
HPV-58
11.3% (12/106)
HPV-66
10.4% (11/106)
HPV-51
9.4% (10/106)
HPV-18
7.5% (8/106)
Multiple Hr-HPV-35, -33, -52, and 58
12.3% (13/106)
Lr-HPV
HPV-6
2−
37.5% (6/16)
HPV-40
25% (4/16)
HPV-44
18.75% (3/16)
HPV-61
18.75% (3/16)
© GinPolMedProject 3 (61) 2021: 001-007
ASC-H, and HSIL compared to ASCUS (P=0.002, 0.001
and 0.001, respectively (Tab. 2.).
Although, the ARTISTIC trial reported HPV-16, -18,
-31, -51, and -52 as the most common Hr-HPV in UK [20].
Correlation between abnormal Pap smears and
CIN: Women with abnormal Pap smears and/or HrHPV positivity were offered colposcopy examination and
cervical biopsy. Out of 122 colposcopy examinations, the
CIN1 was diagnosed in 36.9% (45/122) and CIN2 was
diagnosed in 21.3% (26/122) of cases.
A Chinese study reported HPV-18, followed by HPV52, -16, -58, -33, and -53 as the most common Hr-HPV
in China [22]. In addition, this study, found the most
common Hr-HPV in Kuwait were HPV-16 (36.8%),
HPV-31 (12.3%), HPV-58 (11.3%), HPV-66 (10.4%),
HPV-51 (9.4%), and HPV-18 (7.5%).
DISCUSSION
The LBC approved by the FDA in 1996 as an alternative
to CSS. A systematic review showed that the LBC had an
equivalent performance to CCS [9]. The detection of HPVDNA using PCR based techniques are highly sensitive and
specific, and it has the additional advantages of detecting
small viral concentrations [10]. Variation in the genotype
distribution of Hr-HPV was reported in previous studies
[16-18]. Therefore, this study designed to detect types
of Hr-HPV in abnormal Pap smears and cervical smear
abnormalities associated with Hr-HPV infection.
The prevalence of Hr-HPV in abnormal Pap smears
was 48.2% (106/220), which was higher than that (18.4%)
observed in Qatar, and lower than that (76.4%) observed
in Kazakhstan [16,19].
This can explained by the conservative socio-cultural
norms in Qatar, and by method of HPV-DNA testing
used in this study (Anyplex-II), which is highly sensitive
and specific semi-quantitative real-time PCR method for
detection of HPV-DNA at small viral concentrations [10].
Like other studies [20-22], this study found that the
Hr-HPV detection rate was significantly higher in LSIL,
ASC-H, and HSIL compared to ASCUS (P=0.002, 0.001
and 0.001, respectively), which support the need for HPV
co-testing during cervical cancer screening.
The low prevalence of HPV-18 was not only observed
in this study, but also observed in studies performed in
Qatar and South Korea [16-18]. Variations in the genotype
distribution of Hr-HPV were also reported in South Korea
studies [17,18].
In this study, multiple Hr-HPVs infection (HPV-35,
-33, -52, and 58) were detected in 12.3% of abnormal
Pap smears which is lower than the 44.7% observed in
Brazil [23] and 38.2% in Houston [24]. This could be
explained by the concurrent Hr-HPV infection which
induces effective local or humoral immune response than
that triggered by a single infection, with an overall stronger
immunity against other Hr-HPV infection.
The study from Brazil shows that women with multiple
high-risk HPV infection tend to have high-grade or
persistent CIN lesions [23]. So larger future studies are
needed to confirm the association between multiple HPV
infection and cervical pre-cancerous and/or cancerous lesions.
This study found that the prevalence of Hr-HPV in
abnormal Pap smears was 48.2% (106/220). The most
common Hr-HPV detected in this study was HPV-16
(36.8%), HPV-31 (12.3%), HPV-58 (11.3%), HPV-66
(10.4%), HPV-51 (9.4%), and HPV-18 (7.5%). The HrHPV detected in 39.6% of ASCUS, in 80.2% of LSIL,
in 81.1% (86/106) of ASC-H, and in 83.01 (88/106) of
HSIL. The Hr-HPV detection rate was significantly higher
in LSIL, ASC-H, and HSIL compared to ASCUS.
The ATHENA trial found that about 10% of HPV16 and HPV-18 positive women had high-grade CINs
(≥CIN2) [21].
This study was the first prospective study conducted
in Kuwait and confirms the variations in genotype
distribution of Hr-HPV because of the low prevalence of
HPV-18 observed in this study.
Initially, the Hr-HPV co-testing test recommended for
ASC-US [11]. Based on the recommendations from the
NIH, ASCCP, and ACS [12], the FDA in 2014 approved
the Hr-HPV co-testing as primary screening of cervical
cancer in women ≥25 years at intervals ≥3 years [13].
This study was also the first prospective study conducted
in Kuwait to detect types of Hr-HPV in abnormal Pap
smears using the Anyplex-II which is highly sensitive and
specific PCR method for detection of HPV-DNA at small
viral concentrations.
Tab. 2. The cervical cytology
abnormalities associated with HrHPV infection.
Hr-HPV in ASCUS
Hr-HPV in ASCUS
Hr-HPV in ASCUS
39.6 (42/106)
39.6 (42/106)
39.6 (42/106)
Hr-HPV LSIL
80.2% (85/106)
-
-
Hr-HPV in ASC-H
-
81.1% (86/106)
-
Hr-HPV in HSIL
-
-
83.01% (88/106)
P value (X2 test)
0.002
0.001
0.001
ASC-H: Atypical squamous cells cannot exclude HSIL.
ASCUS: Atypical squamous cells of undetermined significance.
Chi-square (X2) test used for statistical analysis
Data presented as number and percentage (%)
Hr-HPV: High-risk Human papilloma virus
HSIL: High-grade squamous intraepithelial lesion.
LSIL: Low-grade squamous intraepithelial lesion.
3−
REFERENCES
Farghali MM, et al. – Effect of Labor Epidural Analgesia on Delivery of Second Twin: A Prospective Observational Study…
Women refused to participate and/or give consent was
the only limitation faced during this study. Larger future
studies are needed to confirm the association between
multiple HPV infection and cervical pre-cancerous and/or
cancerous lesions.
CONFLICT OF INTERESTS
CONCLUSION
FINANCIAL SUPPORT
Authors declare no conflict of interests related to this
study.
Nil.
The prevalence of Hr-HPV in abnormal Pap smears
was 48.2%. The low prevalence of HPV-18 in this study
confirms the variations in genotype distribution of Hr-HPV.
ETHICS APPROVAL
The Hr-HPV detection rate was significantly higher
in LSIL, ASC-H, and HSIL compared to ASCUS. This
finding supports the recommendation of HPV co-testing
with routine Pap smear in women aged 30-65 years.
Studied women were included in this study after
written consent in accordance with Helsinki declaration
and according to hospital protocol.
1.
Bal MS, Goyal R, Suri AK, et al. Detection of abnormal cervical
cytology in Papanicolaou smears. J Cytol. 2012;29(1):45-7.
2.
Verma K. Early diagnosis of cancer cervix- epidemiology and
incidence. J Cytol. 2001;18:73-89.
3.
Afrakhteh M, Khodakarami N, Moradi A, et al. A study of 13315
Papanicolaou smear diagnoses in Sohada hospital. J Fam Reprod
Health. 2007;1:75-9.
4.
Mitteldorf CATS. Cervical cancer screening from Pap smear to
future strategies. J Bras Patol Med Lab. 2016;52(4):238-245.
5.
Crosbie EJ, Einstein MH, Franceschi S, et al. Human papillomavirus
and cervical cancer. Lancet. 2013;382(9895):889-99.
6.
Tota JE, Chevarie-Davis M, Richardson LA, et al. Epidemiology
and burden of HPV infection and related diseases: implications for
prevention strategies. Prev Med. 2011;53:S12-21.
7.
Saslow D, Castle PE, Cox JT, et al. Gynecologic Cancer Advisory
Group, Garcia F. American Cancer Society Guideline for human
papillomavirus (HPV) vaccine use to prevent cervical cancer and its
precursors. CA Cancer J Clin. 2007;57(1):7-28.
8.
Saslow D, Solomon D, Lawson HW, et al. ACS-ASCCP-ASCP
Cervical Cancer Guideline Committee. American Cancer Society,
American Society for Colposcopy and Cervical Pathology, and
American Society for Clinical Pathology screening guidelines for the
prevention and early detection of cervical cancer. CA Cancer J Clin.
2012;62(3):147-72.
9.
Davey E, Barratt A, Irwig L, et al. Effect of study design and quality
on unsatisfactory rates, cytology classifications, and accuracy in
liquid-based versus conventional cervical cytology: a systematic
review. Lancet. 2006;367(9505):122-32.
10. Abreu AL, Souza RP, Gimenes F, et al. A review of methods for
detect human Papillomavirus infection. Virol J. 2012; 9:262.
11. Solomon D, Schiffman M, Tarone R, et al. Comparison of three
management strategies for patients with atypical squamous cells
of undetermined significance: baseline results from a randomized
trial. J Natl Cancer Inst. 2001;93(4):293-9.
12. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance
for the use of human papillomavirus DNA testing as an adjunct to
cervical cytology for screening. Obstet Gynecol. 2004;103(2):304-9.
13. Abraham J, Stenger M. Cobas HPV test for first-line screening for
cervical cancer. J Community Support Oncol. 2014;12(5):156-7.
14. Committee on Practice Bulletins-Gynecology. ACOG Practice
Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol.
2012;120(5):1222-38.
15. Bouchard-Fortier G, Hajifathalian K, McKnight MD, et al. Cotesting for detection of high-grade cervical intraepithelial neoplasia
and cancer compared with cytology alone: a meta-analysis of
randomized controlled trials. J Public Health (Oxf). 2014;36(1):46-55.
16. Bansal D, Elmi AA, Skariah S, et al. Molecular epidemiology and
genotype distribution of Human Papillomavirus (HPV) among Arab
women in the State of Qatar. J Transl Med. 2014;12:300.
17. So KA, Hong JH, Lee JK. Human Papillomavirus Prevalence and
Type Distribution Among 968 Women in South Korea. J Cancer Prev.
2016;21(2):104-9.
18. Ouh YT, Min KJ, Cho HW, et al. Prevalence of human papillomavirus
genotypes and precancerous cervical lesions in a screening
population in the Republic of Korea, 2014-2016. J Gynecol Oncol.
2018;29(1):e14.
19. Aimagambetova G, Azizan A. Epidemiology of HPV Infection and
HPV-Related Cancers in Kazakhstan: a Review. Asian Pac J Cancer
Prev. 2018;19(5):1175-80.
20. Sargent A, Bailey A, Almonte M, et al. ARTISTIC Study Group.
Prevalence of type-specific HPV infection by age and grade
of cervical cytology: data from the ARTISTIC trial. Br J Cancer.
2008;98(10):1704-9.
21. Wright TC Jr, Stoler MH, Sharma A, et al. Evaluation of HPV-16
and HPV-18 genotyping for the triage of women with high-risk HPV+
cytology-negative results. Am J Clin Pathol. 2011;136(4):578-86.
22. Wang X, Zeng Y, Huang X, et al. Prevalence and Genotype
Distribution of Human Papillomavirus in Invasive Cervical Cancer,
Cervical Intraepithelial Neoplasia, and Asymptomatic Women in
Southeast China. Biomed Res Int. 2018;2018:2897937.
23. De Brot L, Pellegrini B, Moretti ST, et al. Infections with multiple
high-risk HPV types are associated with high-grade and persistent
low-grade intraepithelial lesions of the cervix. Cancer Cytopathol.
2017;125(2):138-143.
24. Salazar KL, Zhou HS, Xu J, et al. Multiple Human Papilloma Virus
Infections and Their Impact on the Development of High-Risk
Cervical Lesions. Acta Cytol. 2015;59(5):391-8.
−4